RxDoctor Payments Data

Nichol Burchfield, PA

Physician Assistant · Elkhorn City, KYNPI 1497893085

Payments from drug & device makers

$2,960in general payments, 2019–2025

Across 111 payments — averaging $26.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$867
  • AbbVie$527
  • Boehringer Ingelheim$322
  • Novartis$256
  • Atricure, Inc.$204
  • Indivior Inc.$194
  • plus $589 from 16 others

What the payments were for

  • Food & beverage$2,960100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,960 in reported general payments places this provider in the 85th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$27,902
Medicare patients
112
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide64$65,344
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$30,216
JanuviaSitagliptin Phosphate32$21,968
JardianceEmpagliflozin29$21,570
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$19,736
FarxigaDapagliflozin Propanediol27$16,983
WegovySemaglutide12$15,926
GlyxambiEmpagliflozin/Linagliptin19$12,723
Spiriva RespimatTiotropium Bromide21$12,145
EntrestoSacubitril/Valsartan11$11,304
Repatha SureclickEvolocumab11$6,026
Dexlansoprazole DrDexlansoprazole24$5,835
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,201
Albuterol Sulfate HfaAlbuterol Sulfate108$3,664
Ventolin HfaAlbuterol Sulfate56$3,111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$45$65,34464 claims
Boehringer IngelheimJardiance, Glyxambi, Spiriva Respimat$322$46,43869 claims
AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere$867$41,92072 claims
GSKTrelegy Ellipta$51$30,21646 claims
NovartisEntresto$256$11,30411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Elkhorn City

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →